Background: Treatment of germ cell tumours with cisplatin-based chemotherapy results in cure for the majority of patients. There is, however, a small but significant mortality rate, reported to be higher in patients with multiple co-morbidities. Case Report: We report our management of a renal transplant patient with spina bifida, who was diagnosed with stage IIIC, poor-risk, non-seminomatous germ cell carcinoma. A marker-negative partial response, which has been maintained more than 2 years following completion of treatment, was seen following chemotherapy with cisplatin and etoposide. Performance status has been preserved at pre-treatment levels. Conclusion: Administration of cisplatin-based chemotherapy is feasible for treatment of renal transplant patients with advanced non-seminomatous germ cell tumours. Treatment strategies require careful planning and monitoring. Dose modifications may be required. This case highlights a favourable outcome in spite of multiple obstacles to ideal management.

1.
International Germ Cell Cancer Collaborative Group: International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
2.
Fizazi K, Prow DM, Do K-A, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu S-M, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ: Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer 2002;86:1555-1560.
3.
Honecker F, Bokemeyer C: Patients with advanced nonseminomatous germ-cell tumour: the art of the start. Ann Oncol 2010;21:1569-1571.
4.
O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A: Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003;14:91-96.
5.
Kawai K, Hinotsu S, Tomobe M, Akaza H: Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity. Jpn J Clin Oncol 1998;28:546-550.
6.
Chumlea WC, Guo SS, Steinbaugh ML: Prediction of stature from knee height for black and white adults and children with application to mobility-impaired or handicapped persons. J Am Diet Assoc 1994;94:1385-1388.
7.
7 Joel SP, Shah R, Clark PI, Slevin ML: Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996;14:257-267.
8.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative work-group: Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit Care 2004;8:R204-R212.
9.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205.
10.
Tsaur I, Karalis A, Probst M, Blaheta RA, Scheuermann EH, Gossmann J, Kachel HG, Hauser IA, Jonas D, Obermüller N: Development of urological cancers in renal transplant recipients: 30-year experience at the Frankfurt Transplant Center. Cancer Sci 2010;101:2430-2435.
11.
Osiason A, Polackwich R: Curative, platinum-based cytotoxic drug therapy in a renal transplant recipient with metastatic testicular cancer. Cancer 1986;4:850-851.
12.
Vogelzang NJ: Cisplatin and etoposide for metastatic testis cancer in a renal transplant recipient. Urology 1990;143:1235-1236.
13.
Vogelzang NJ: Cisplatin based chemotherapy in a renal transplant recipient. Cancer 1992;12:3015.
14.
Dahl O, Vagstad G, Iversen B: Cisplatin-based chemotherapy in a renal transplant recipient with metastatic germ cell testicular cancer. Acta Oncologica 1996;35:759-761.
15.
Lindley CM, Gordon TR, Tremont SJ: Cisplatin-based chemotherapy in a renal transplant recipient. Cancer 1991;68:1113-1117.
16.
Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP: Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15:1844-1852.
17.
Lazarev I, Bogomolni L, Shani-Shrem N, Shnaider A, Ariad S, Mermershtain W: Successful treatment of mediastinal seminoma in a hemodialysis patient. Onkologie 2012;35:275-278.
18.
Wójcik J, Bułło B, Jassem J, Rutkowski B: (Platinum-based chemotherapy in renal transplant recipients with malignancies: a case report and review of literature). Pol Merkur Lekarski 1998;5:145-146 (article in Polish).
19.
Modlin CS, Flechner SM, Penn I: Testicular seminoma originating in an undescended testis in a renal allograft recipient. Urology 1996;48:145-148.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.